NCT01231815

Brief Summary

Heart transplantation is the ultimate therapeutic option in patients with end-stage heart failure. Since advances in the treatment of acute rejection has increased early transplant survival, cardiac allograft vasculopathy (CAV) is the main factor limiting long-term survival. The prevalence of angiographically proven CAV is high, documented in 40-50% of transplant recipients 5 years after transplantation. Therefore, annual coronary angiography remains widely used to monitor transplanted patients, although pathologic studies and intravascular ultrasonography have demonstrated that coronary angiography underestimates the severity of CAV. Perfusion SPECT may underestimate allograft vasculopathy in case of diffuse coronary lesions. In this setting, the assessment of coronary reserve by means of Positron Emission Tomography (PET) and perfusion cardiac magnetic resonance imaging (CMR) have not been investigated.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Nov 2010

Longer than P75 for not_applicable

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 29, 2010

Completed
3 days until next milestone

First Posted

Study publicly available on registry

November 1, 2010

Completed
Same day until next milestone

Study Start

First participant enrolled

November 1, 2010

Completed
4.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2014

Completed
Last Updated

April 9, 2014

Status Verified

April 1, 2014

Enrollment Period

4.1 years

First QC Date

October 29, 2010

Last Update Submit

April 8, 2014

Conditions

Keywords

Heart transplantation

Outcome Measures

Primary Outcomes (1)

  • To compare the coronary flow reserve by a quantitative method (PET ...

    6 months

Study Arms (2)

PET

EXPERIMENTAL

15O-H2O PET

Radiation: 15O-H2O PET -

MRI

EXPERIMENTAL

MRI

Radiation: MRI

Interventions

15O-H2O PET -RADIATION

Assessment of coronary reserve using PET

PET
MRIRADIATION

Assessment of coronary reserve using MRI

MRI

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient with heart transplantation \> 3 years
  • Candidate to a routine coronary angiography
  • Age \> 18 years old
  • signed informed consent

You may not qualify if:

  • Pregnancy or breast feeding women
  • Recent acute coronary syndrome (\<4weeks)
  • High Blood Pressure ((SBP \>=180 mmHg or DBP \>=110 mmHg)
  • Significant ventricular or supraventricular arrythmia
  • Atrioventricular 2nd or 3rd degree blocks, long QT syndrome
  • Standard contraindications to MRI including pacemaker/defibrillator, metallic clips on brain aneurysms, metal fragment in the eye etc...
  • Congestive heart failure
  • Hemodynamic instability
  • Intolerance or contraindication to adenosine (history of asthma or bronchoplastic disease).
  • Severe and known pulmonary artery hypertension
  • Severe hypotension \< 90 mmHg
  • Contraindication to contrast iodinated media (allergy, patients with chronic renal failure with creatinine clearance \< 50 ml/min, multiple myeloma, hyperthyroidism,...)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

CHU de Caen - GIP Cyceron

Caen, 14000, France

RECRUITING

CHU de Rouen

Rouen, 76000, France

RECRUITING

MeSH Terms

Conditions

Heart Diseases

Condition Hierarchy (Ancestors)

Cardiovascular Diseases

Study Officials

  • Alain Manrique, MD

    GIP Cyceron - CHU de Caen

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Alain MANRIQUE, MD

CONTACT

Denis AGOSTINI, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 29, 2010

First Posted

November 1, 2010

Study Start

November 1, 2010

Primary Completion

December 1, 2014

Study Completion

December 1, 2014

Last Updated

April 9, 2014

Record last verified: 2014-04

Locations